Doxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK?

Abstract:

:Macrolide monotherapy is currently recommended as first-line treatment of mild-to-moderate community-acquired pneumonia (CAP) in penicillin-intolerant/allergic individuals in the UK. However, resistance rates among the commonest cause, Streptococcus pneumoniae, now exceed 10% in the UK and a review of alternative agents is therefore timely. This review considers the relative merits of two agents, doxycycline and moxifloxacin, which are candidates to replace macrolides for second-line therapy of non-severe CAP.

authors

Ludlam HA,Enoch DA

doi

10.1016/j.ijantimicag.2008.02.003

subject

Has Abstract

pub_date

2008-08-01 00:00:00

pages

101-5

issue

2

eissn

0924-8579

issn

1872-7913

pii

S0924-8579(08)00079-4

journal_volume

32

pub_type

杂志文章,评审